Press releases

Eevia Health Plc commissions new analytical equipment for analyzing anthocyanins and polyphenols

Eevia Health has commissioned a new High-Performance Liquid Chromatography (HPLC) analytical equipment from Shimadzu, which significantly increases the capacity to undertake analyses of polyphenols.

The new HPLC is a Shimadzu Nexera Lite 440 bar. It has automated sampling functionality and a huge range of specialized and advanced features, which constitutes the state of the art in liquid chromatography analytics.

The HPLC-based methods are the gold standard for analyzing anthocyanins and polyphenols. It provides not only total polyphenols but breaks them down into each specific anthocyanin. For bilberry, there are 16 recognized anthocyanins which also should appear with a certain profile to pass ID test criteria under European and US pharmacopeia monographs. 

The new HPLC from Shimadzu significantly improves the analytical capacity of Eevia and therefore enables the company to increase efforts to control the raw material Eevia purchases, internal process control, and analytics necessary for product release to the market.

"I am extremely pleased with the new HPLC. It provides a much higher capacity, significantly better specificity, and has an ease of use which is remarkable. We can now keep up with both Internal Process Control samples, as well as raw material and finished goods release jobs." says Joonas Hast, Eevia Health Lab Technician.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          
Telephone: +358 400 22 5967   


Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.

To learn more, please visit or follow Eevia Health on LinkedIn@EeviaHealth. 


Eevia Health Plc, ("Eevia" or "The Company"), has received sales order from Taiwan of c. 13 KEUR for an organically certified bilberry extract.


Eevia Health Plc ("Eevia" or "The Company") by the CEO Stein Ulve will present at the event "Stora Aktiedagarna" in Stockholm, which is arranged between March 13th and March 15th 2023 by Aktiespararna.


Eevia Health Plc ("Eevia" or "The Company") has received a 20 KEUR sales order for Feno-Chaga®  Organic from a health-food customer in Finland.


Eevia Health Plc ("Eevia" or "The Company") has received a 12 KEUR sales order for Feno-Chaga® M from a health-food customer in Finland.


Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the fourth quarter of 2022.


Eevia Health Plc, ("Eevia" or "The Company"), has been certified by OK Kosher, US.


Eevia Health Plc ("Eevia" or "The Company") is welcoming Matleena Kotila as the new Commercial manager. At the same time, Tommi Kilpeläinen's contract as Scientific Product Manager was discontinued in the trial period.


Eevia Health Plc ("Eevia" or "The Company") has received a positive decision from Business Finland for a business development grant of 243 840 EUR. The grant is a 50% financing of a total project budget of 487.680 EUR. The project has two work packages.


Eevia Health Plc ("Eevia" or "The Company") has received a 12 KEUR sales order for a Chaga extract from its US distributor Barrington Nutritionals.